• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Immunomedics pursues breast imaging

Article

Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, last month submitted to the European Medicines Evaluation Agency (EMEA) a regulatory application for use of its lead product, CEA-Scan, in breast imaging applications. The company believes its

Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, last month submitted to the European Medicines Evaluation Agency (EMEA) a regulatory application for use of its lead product, CEA-Scan, in breast imaging applications. The company believes its clinical trials have demonstrated that the monoclonal antibody-based agent correctly identifies cancer in 82% of the women studied, and in 91%, cancer was correctly ruled out. CEA-Scan is already being sold in the U.S. and Europe for the detection of colorectal cancer.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.